Imugene (ASX:IMU) confirms “favourable” survival outcome in HER-Vaxx phase two trial
Imugene (IMU) reports positive and “favourable” survival outcome in final data from…
Imugene Limited (ASX:IMU)
About Imugene Limited
Key Information
IMU In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 09.15am 27/06/2022 | Investor Webinar - Final HER-Vaxx Overall Survival Results | 186.5KB | 3.0K |
| 08.24am 27/06/2022 | Price Sensitive PS Final HER-Vaxx Phase 2 Trial Overall Survival Results | 224.59KB | 66K |
| 14/06/2022 | Change of Director's Interest Notice - CW | 172.19KB | 24K |
| 09/06/2022 | Change of Director's Interest Notice - LR | 370.15KB | 11K |
| 08/06/2022 | Notice Under Section 708A | 126.16KB | 2.8K |
| 08/06/2022 | Application for quotation of securities - IMU | 36.39KB | 873 |
| 01/06/2022 | IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD | 121.37KB | 12K |
| 31/05/2022 | IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 | 118.67KB | 13K |